Akane Kawai, Yuji Nagatomo, Midori Yukino-Iwashita, Ryota Nakazawa, Akira Taruoka, Yusuke Yumita, Asako Takefuji, Risako Yasuda, Takumi Toya, Yukinori Ikegami, Nobuyuki Masaki, Yasuo Ido, Takeshi Adachi
A wide range of anti-myocardial autoantibodies have been reported since the 1970s. Among them, autoantibodies against the β1 -adrenergic receptor (β1 AR-AAb) have been the most thoroughly investigated, especially in dilated cardiomyopathy (DCM). Β1 AR-Aabs have agonist effects inducing desensitization of β1 AR, cardiomyocyte apoptosis, and sustained calcium influx which lead to cardiac dysfunction and arrhythmias. Β1 AR-Aab has been reported to be detected in approximately 40% of patients with DCM, and the presence of the antibody has been associated with worse clinical outcomes...
September 10, 2023: Journal of Cardiovascular Development and Disease